Showing results (1371-1380 of 5,920) with videos related to

Sort By:
Pageof 592
Arthritis Research & Therapy|July 18, 2024
Stabilizing the integrity of intestinal barrier to control arthritisGeorge D Kalliolias, Athanasios G Papavassiliou
Arthritis Research & Therapy|April 12, 2024
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuationEmily E Holladay, Amy S Mudano, Fenglong Xie, et al.
Arthritis Research & Therapy|April 10, 2024
Usability and preliminary effectiveness of an app-based physical activity and education program for people with hip or knee osteoarthritis - a pilot randomized controlled trialF Weber, C Kloek, S Stuhrmann, et al.
Arthritis Research & Therapy|January 23, 2024
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritisJohanna Straube, Shoiab Bukhari, Shalom Lerrer, et al.
Arthritis Research & Therapy|February 8, 2024
Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioRegDubravka Ukalovic, Burkhard F Leeb, Bernhard Rintelen, et al.
Arthritis Research & Therapy|January 27, 2024
Apolipoproteins and the risk of giant cell arteritis-a nested case-control studyKarin Wadström, Lennart T H Jacobsson, Aladdin J Mohammad, et al.
Arthritis Research & Therapy|February 6, 2024
Patients with obesity have more inflamed joints and higher CRP levels during the disease course in ACPA-positive RA but not in ACPA-negative RAN K den Hollander, A M P Boeren, A H M van der Helm-van Mil, et al.
Arthritis Research & Therapy|January 17, 2024
Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarrayJing Huang, Honglin Zhu, Sijia Liu, et al.
Arthritis Research & Therapy|September 7, 2024
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)Xiaomei Leng, Piotr Leszczyński, Slawomir Jeka, et al.
Arthritis Research & Therapy|September 17, 2024
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patientsGilberto Cincinelli, Gabriella Maioli, Cristina Posio, et al.
Pageof 592